Pharmacokinetics of Vancomycin in ICU Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-10-31

Study Completion Date

2016-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vancomycin is frequently under-dosed in ICU patients during the first 24-48 hours of treatment. Glomerular hyperfiltration syndrome, increased drug volume of distribution, vasopressor use, male sex and hypoalbuminemia are identified risk factor for vancomycin underdosing in ICU patients, among others.

To date, bedside estimation of vancomycin volume of distribution is challenging, and new methods for optimizing drug administration are required.

The Picco device is a moderately invasive hemodynamic monitoring system, providing parameters that may help estimation of vancomycin pharmacokinetics parameter.

The aim of this study is to test whether addition of hemodynamic parameters would improve pharmacokinetics modelling of vancomycin concentration in ICU patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Utility of Vancomycin Loading: A Pharmacokinetic Analysis in Critically Ill Patients

NCT01157533

Infection

TERMINATED NA

Cystatin-C C-guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project

NCT02945241

Methicillin-resistant Staphylococcus Aureus Sepsis Critical Illness

COMPLETED PHASE1

Pharmacokinetics of Vancomycin in Adults Receiving ECMO

NCT00281281

Extracorporeal Membrane Oxygenation

COMPLETED PHASE4

Study of Obese Patients Comparing Two Vancomycin Loading Dose Regimens

NCT02764359

Infection Sepsis Obesity

UNKNOWN NA

Dose Enhancement of Vancomycin IN Everyday Patients

NCT01427842

Vancomycin Therapy

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Suspected Infection With Vancomycin Susceptible Bacterial Strains

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patient hospitalized in intensive care unit
* under intravenous vancomycin started during current ICU hospitalization
* with at least one vancomycin serum concentration available
* under hemodynamic monitoring with the Picco ® device

Exclusion Criteria

* vancomycin treatment for less than 24 hours
* vancomycin concentration in serum unavailable
* rare comorbidities influencing vancomycin pharmacokinetics

* myeloma
* cystic fibrosis
* burn injury on more than 20 % of the body surface
* previous inclusion in present study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No